MNG1210
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.646
- E2F_TARGETS+0.641
- INTERFERON_ALPHA_RESPONSE+0.624
- INTERFERON_GAMMA_RESPONSE+0.601
- ALLOGRAFT_REJECTION+0.524
- MITOTIC_SPINDLE+0.505
- MYC_TARGETS_V1+0.484
- MYC_TARGETS_V2+0.468
- PROTEIN_SECRETION+0.450
- MTORC1_SIGNALING+0.437
Top 10 suppressed
- MYOGENESIS-0.328
- BILE_ACID_METABOLISM-0.314
- PANCREAS_BETA_CELLS-0.274
- OXIDATIVE_PHOSPHORYLATION-0.264
- KRAS_SIGNALING_DN-0.252
- ADIPOGENESIS-0.242
- XENOBIOTIC_METABOLISM-0.193
- FATTY_ACID_METABOLISM-0.188
- HEDGEHOG_SIGNALING-0.139
- ESTROGEN_RESPONSE_LATE-0.115
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.956 |
| 2 | SRR934780 | — | — | 0.915 |
| 3 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.911 |
| 4 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.910 |
| 5 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.910 |
| 6 | TCGA-GC-A3RC-01A-11R-A22U-07 | — | — | 0.905 |
| 7 | 33233781-A799-4610-86FC-C836713D31AA | — | — | 0.904 |
| 8 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.903 |
| 9 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.902 |
| 10 | SRR934956 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.646 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.641 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.624 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.601 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.524 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.505 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.484 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.468 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.437 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.425 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.405 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.386 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.333 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.303 | Idelalisib | — uncovered |
| APOPTOSIS | 0.284 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.267 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.262 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.257 | Inavolisib | — uncovered |